Clair mills today
- •
Dr. Gordon B. Mills earned his M.D. and Ph.D. in biochemistry and completed his training in Obstetrics and Gynecology at the University of Alberta. Prior to moving to OHSU, Dr. Mills was at the MD Anderson Cancer Center, the number one ranked Cancer Center in the United States. He fulfilled multiple roles including founding chair of the Department of Systems Biology, co-Director of the Sheikh Zayed bin Sultan Al Nahyan Institute for Personalized Cancer Therapy co-Director of the Kleberg Center for Molecular Markers and holds the Olga Keith Wiess Distinguished University Chair for Cancer Research at the MD Anderson Cancer Center.
At the OHSU Knight Cancer Institute, Dr. Mills is Director of Precision Oncology and SMMART trials. He is responsible for the implementation of an integrated program of tumor analysis, decision-making and implementation of novel precision oncology trials. The key goal will be to use serial tumor and liquid biopsies to evaluate and target adaptive responses in real time to interdict cancer evolution.
Dr. Mills' research ranges across: 1) translating
- •
Prof. Gordon B. Mills MD Anderson Cancer Center, USA
Gordon B. Mills, MD, PhD, was recruited to The University of Texas M. D. Anderson Cancer Center (MDACC) in 1994, where he holds the rank of Professor with joint appointments in Systems Biology, Breast Medical Oncology and Immunology, and serves as chairman of the Department of Systems Biology. Dr. Mills...read moreis Director of the Kleberg Center for Molecular Markers and Director for the South Campus Research Building II. Dr. Mills is also co-Director of the Sheikh Zayed bin Sultan Al Nahyan Institute for Personalized Cancer Therapy. The Center and the Institute are responsible for developing and implementing personalized molecular medicine at MDACC. Dr. Mills has published extensively on the molecular analysis of cancer and currently serves as principal investigator or project investigator on many national peer review grants including Stand Up To Cancer, NIH/NCI SPOREs U24 and PPGs, Department of Defense, CPRIT and Komen Foundation grants, and is a collaborator on multiple other national grants. He has recently been awarde
- •
Gordon B. Mills
Oncology researcher
Gordon B. Mills is the Wayne and Julie Drinkward Endowed Chair in Precision Oncology, Director of Precision Oncology, Director of SMMART Trials and Professor in Cell, Development and Cancer Biology in the Knight Cancer Institute at Oregon Health & Science University.
He is most well known for his discoveries in the PI3K pathway in breast cancer.[1]
Mills received his BS in 1975, MD in 1977, and PhD in 1984, all from the University of Alberta, Edmonton.[2] He did a postdoc in immunology at the Hospital for Sick Children in Toronto and then joined the faculty at the University of Toronto in 1985 as an assistant professor and director of oncology research. He was recruited to MD Anderson in 1994.[1] He held multiple leadership positions at the MD Anderson Cancer Center including Chair of Systems Biology, Director of the Kleberg Center for Molecular Markers and was co Director of the Khalifa Institute for Personalized Cancer Therapy. He held the Weiss Distinguished University Chair. He was recruited to the
Copyright ©dadtori.pages.dev 2025